Particle.news

Download on the App Store

HHS Winds Down $500M in mRNA Vaccine Projects to Support Broader Platforms

Data showing mRNA vaccines underperform against respiratory infections prompted HHS to redirect $500 million toward whole-virus vaccine strategies, novel platforms, expanded non-mRNA research

HHS Secretary Robert F. Kennedy Jr., is seen on stage at the inaugural Great American Farmers Market on the National Mall on Monday, August 4, 2025.
Image
Image
Image

Overview

  • HHS will wind down 22 BARDA contracts worth $500 million that funded mRNA vaccine development for respiratory viruses
  • The canceled projects led by Pfizer, Moderna, Sanofi Pasteur and other firms targeted vaccines against COVID-19, flu and H5N1
  • HHS said other mRNA applications remain unaffected and approved mRNA vaccines for COVID-19 and RSV will continue in use
  • Experts including Rick Bright and Mike Osterholm warned that ending mRNA research now could weaken future pandemic preparedness
  • Kennedy affirmed support for safe, effective vaccines and announced a shift toward whole-virus and novel vaccine platforms with work on a potential universal vaccine